๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2857 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 27 Sep 2026, 03:15 UTC
2857
Studies in scope
industry-sponsored, all four open statuses
1391
Recruiting now
open to new participants
547
Lead sponsors
across recruiting studies
Top sites
London 13 Manchester 5 Oxford 2 Bristol 2 Sheffield 2
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in London

13 of 2857 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360Sickle Cell Disease
CSL Behring
Phase 2
63
London
2026-02-02
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865Sickle Cell Disease
Sanofi
Phase 3
192
London
2025-08-12
Recruiting
PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
NCT06923111Sickle Cell Disease
Nova Laboratories Limited
Observational
180
Basildon, Cardiff, London, Manchester, Oxford
2025-06-09
Active, closed
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970Sickle Cell Disease
Agios Pharmaceuticals, Inc.
Phase 2
59
London
2025-05-01
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268Sickle Cell Disease
Novo Nordisk A/S
Phase 3
510
Cambridge, London
2025-02-17
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226Sickle Cell Disease, Thalassemia
Novo Nordisk A/S
Phase 3
480
London, Manchester, Sheffield
2025-01-10
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
NCT06198712Sickle Cell Disease
Forma Therapeutics, Inc.
Phase 2
95
London, Manchester
2023-01-12
Recruiting
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
NCT05431088Sickle Cell Disease
Pfizer
Phase 2/3
389
Bristol, London
2022-09-22
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies
Vertex Pharmaceuticals Incorporated
Phase 3
13
London
2022-05-02
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780Sickle Cell Disease
Agios Pharmaceuticals, Inc.
Phase 2/3
286
London, Cambridge, Manchester
2022-02-11
Active, closed
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
NCT04624659Sickle Cell Disease
Forma Therapeutics, Inc.
Phase 3
450
Leicester, London, Oxford, Sheffield
2021-01-29
By invitation
A Long-term Follow-up Study in Participants Who Received CTX001
NCT04208529Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases
Vertex Pharmaceuticals Incorporated
Phase 3
160
London
2021-01-20
Active, closed
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
NCT04053803Sickle Cell Disease
Imara, Inc.
Phase 2
30
Bristol, London
2019-05-22
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,857 studies in total at the last sync on 27 Sep 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in London that also match the filters currently applied.

How many clinical trials are recruiting in London?

7 of the 13 studies on this page are recruiting new participants as of the 27 Sep 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 13 studies
PhaseStudiesRecruitingShare
Phase 36346.2%
Phase 24230.8%
Phase 2/32115.4%
Observational117.7%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
Agios Pharmaceuticals, Inc.20
Forma Therapeutics, Inc.21
Novo Nordisk A/S22
Vertex Pharmaceuticals Incorporated20
CSL Behring11
Imara, Inc.10
Nova Laboratories Limited11
Pfizer11
Sanofi11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.